These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15357537)

  • 1. Considerations in the pharmacoeconomics of glaucoma.
    Hirsch JD
    Manag Care; 2002 Nov; 11(11 Suppl):32-7. PubMed ID: 15357537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Health outcomes analysis and its applications].
    Carrera-Hueso FJ
    Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The power of pharmacoeconomics.
    Healthc Exec; 2000; 15(1):44-5. PubMed ID: 11067028
    [No Abstract]   [Full Text] [Related]  

  • 5. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacoeconomics of high-cost biotechnology products.
    Dana WJ; Farthing K
    Pharm Pract Manag Q; 1998 Jul; 18(2):23-31. PubMed ID: 10185236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial neural network in pharmacoeconomics.
    Polak S; Skowron A; Mendyk A; Brandys J
    Stud Health Technol Inform; 2004; 105():241-9. PubMed ID: 15718613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic planning for applied pharmacoeconomics programs.
    Wanke LA; Ryan GM
    Pharm Pract Manag Q; 1996 Jan; 15(4):64-74. PubMed ID: 10153846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacoeconomics. Potent drugs, diseases are costly].
    Flaten O
    Tidsskr Nor Laegeforen; 1994 Apr; 114(11):1345-6. PubMed ID: 8079219
    [No Abstract]   [Full Text] [Related]  

  • 13. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
    Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
    Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics in the era of individualized medicine.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2008 Aug; 84(2):179-82. PubMed ID: 18679176
    [No Abstract]   [Full Text] [Related]  

  • 15. Glaucoma arrives on managed care's doorstep.
    Mansukani SS
    Manag Care; 2002 Nov; 11(11 Suppl):6-9. PubMed ID: 15357533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of new medications for common chronic ophthalmic diseases.
    Hirsch JD; Morello C; Singh R; Robbins SL
    Surv Ophthalmol; 2007; 52(6):618-33. PubMed ID: 18029270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacoeconomics of asthma].
    Jahnz-Rózyk K; Targowski T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical review of the full economic evaluations of pharmacological treatments for glaucoma.
    Koleva D; De Compadri P; Virgili G; Nobili A; Garattini L
    J Med Econ; 2008; 11(4):719-41. PubMed ID: 19450078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
    Henry D; Taylor C
    Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.